ADVERTISEMENT
Identifying Predictors of Biomarker Testing in Metastatic Non-Small Cell Lung Cancer
Nicholas Robert, MD, Ontada, Irving, TX, discusses real-world biomarker testing rates for metastatic non–small cell lung cancer (mNSCLC) within The US Oncology Network, examining patient factors associated with rates of biomarker testing.
This research identified histologic and geographic factors associated with the likelihood of testing, as well as the significance of practice size, concluding that understanding clinical and social determinants of health is critical when evaluating interventions to improve testing rates.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Current Issue
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Subscribe
Advertisement
Advertisement
Advertisement
Recent Stories
Advertisement